To confirm our protocol would be effective at targeting other genes in ILC2s, we performed a pilot experiment with sgRNAs targeting IL10, which we and others have linked to ILC2s immunoregulatory effects in the context of allergy (11), cell therapy approaches for transplantation (28) and Graft-versus-Host Disease (GvHD) (31). This evidence concerns the gene IL10 and allergic disease.